top of page
Browse by category
Search

China faces urgent public health challenges with rapid increase in early-onset T2DM
Researchers from Peking University, China, have revealed a sharp rise in the burden of early-onset type 2 diabetes mellitus (T2DM) among...


Micronutrient deficiencies are common in people with type 2 diabetes
Micronutrient deficiencies are common in people with type 2 diabetes, according to the findings of a pooled data analysis of the...


RYGB and SG lower health care costs for T2DM patients
In patients with type 2 diabetes, Roux-en-Y gastric bypass and sleeve gastrectomy for weight loss may be effective for reducing long-term...

COMBINE trial: Glucose clamp technique as part of a new type 2 diabetes research trial
Researchers at Leicester Diabetes Centre (LDC) have successfully started using the glucose clamp technique as part of a new type 2...


First patient enrolled in Endogenex’ ReCET clinical study
Endogenex has enrolled the first patient in the Re-Cellularization via Electroporation Therapy ( ReCET) clinical study, multi-centre,...


ReCET procedure plus semaglutide may eliminate insulin dependency in T2D
A promising new treatment strategy for type 2 diabetes (T2D) that combines a novel procedure known as ReCET (Re-Cellularization via...

Bariatric surgery outperforms GLP-1 diabetes drugs for kidney protection
For patients with type 2 diabetes, obesity and chronic kidney disease, bariatric surgery was associated with a significant decrease in...


T2DM patients at higher risk of certain cancers could be identified by a simple blood test
Individuals with type 2 diabetes who are at higher risk of certain cancers could be identified by a simple blood test, according to...


Tirzepatide reduced the risk of developing T2Dm by 94% in adults with pre-diabetes and obesity or overweight
Eli Lilly and Company has announced positive topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating...


First patient enrolled in a Phase 2 Study in T2DM patients with Olatec's NLRP3 inhibitor dapansutrile
The first patient with T2DM and diabetes-related complications has been enrolled in the clinical trial, DAPAN-DIA, in Basel, Switzerland,...
Browse by tag





bottom of page